Pless, Miklos <br/><br/>
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2004 
 - 1299-305 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.ccr-0977-03  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenosylmethionine Decarboxylase--antagonists & inhibitors<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amidines--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Indans--pharmacology<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Polyamines--antagonists & inhibitors<br/>Prognosis<br/>Recurrence<br/>Time Factors<br/>Treatment Outcome